Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. filed an amended report to add XBRL data to a prior disclosure without changing any of the original information. The company’s Board of Directors increased its size from eleven to twelve members and appointed Dr. Thomas Lynch as a new independent Class I director effective June 2, 2026.
Dr. Lynch’s term runs until the 2028 annual meeting of stockholders, and he will serve on the Board’s Human Capital Committee. He will receive cash and equity compensation in line with other non-employee directors, including a stock unit award vesting in three equal installments on June 26 of 2027, 2028, and 2029.
Natera, Inc. reported the results of its annual stockholder meeting, where investors approved an amendment to the Amended and Restated 2015 Equity Incentive Plan, increasing shares reserved for issuance by 3.2 million shares of common stock.
Stockholders elected three Class II directors and one Class I director, each receiving more votes "for" than "withheld." They also ratified Ernst & Young LLP as independent registered public accounting firm, approved the advisory vote on executive compensation, and supported holding that advisory vote every year.
As of the record date, 142,778,493 shares were outstanding and entitled to vote, and 130,691,097 shares were represented in person or by proxy, satisfying quorum requirements.
Morgan Stanley Smith Barney LLC submits a Form 144 notice listing 100,000 Common shares to be sold, described as proceeds from Previously Exercised Stock Options for cash, with an associated aggregate amount of $21,923,000. The filing also reports 10b5-1 sales by Matthew Rabinowitz of 75,000 and 50,000 Common shares on 03/13/2026 and 03/16/2026, respectively.
Natera, Inc. director Marcus Gail Boxer reported an exercise-and-sell transaction in company stock. On June 5, 2026, he exercised stock options for 11,000 shares of Common Stock at an exercise price of $22.83 per share and sold 11,000 shares in multiple open-market trades.
The sales were executed in several tranches at weighted average prices around $216–$219 per share, with detailed price ranges disclosed in the notes. Following these transactions, Boxer directly owns 6,183 shares of Natera Common Stock, and the option position related to these 11,000 shares is fully exercised.
Natera, Inc. filed an initial ownership report for Thomas J. Lynch Jr., who is identified as a director of the company. This Form 3 does not list any stock transactions or current holdings, and it confirms he is not classified as a ten percent owner based on this filing.
Natera, Inc. CEO and President Steven Leonard Chapman reported open-market sales of 41,124 shares of common stock on June 4, 2026. The 14 separate transactions were executed at weighted-average prices, with footnotes showing sale prices ranging from about $211.89 to $227.21 per share under a pre-arranged Rule 10b5-1 trading plan adopted and later amended by the reporting person. After these sales, Chapman continues to hold 108,743 shares of Natera common stock directly.
Natera, Inc. expanded its Board of Directors from eleven to twelve members and appointed Thomas Lynch as a new director, effective June 2, 2026. He will serve as a Class I director with a term running until the 2028 annual stockholder meeting and has been deemed independent under Nasdaq standards. Lynch will join the Board’s Human Capital Committee and receive cash and equity compensation in line with Natera’s existing non-employee director program. His initial equity award will vest in three equal installments on June 26 of 2027, 2028, and 2029. The company also plans to enter into an indemnification agreement with him and notes there are no family relationships or related-party transactions requiring disclosure.
Steven L. Chapman reported proposed and recent transactions in Common stock via a Form 144 filing. The filing lists multiple reported sales during the past three months: 5/4/2026: 909 shares for $189,283.07; 5/1/2026: 902 shares for $185,956.32; 4/29/2026: 3,352 shares for $649,909.13; 4/28/2026: 2,313 shares for $463,027.24; 4/27/2026: 5,838 shares for $1,191,774.74; and 3/10/2026: 5,623 shares for $1,147,838.17. The filing also references Restricted Stock with an original grant date of 01/21/2022.